HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- (3- (4- cyano- 3- trifluoromethylphenyl)- 5,5- dimethyl- 4- oxo- 2- thioxoimidazolidin- 1- yl)pyridine- 2- sulfonic acid amide

an androgen receptor antagonist and antineoplastic agent; structure in first source

Also Known As:

CH 5137291; CH-5137291; CH5137291

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - 6-(3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)pyridine-2-sulfonic acid amide: 3
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - 6-(3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)pyridine-2-sulfonic acid amide: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Imidazolidines: 39
        Hydantoins: 306
        Thiohydantoins: 19
        6-(3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)pyridine-2-sulfonic acid amide: 3

Experts

1.	Ishikura, Nobuyuki: 3 articles (04/2015 - 12/2010)
2.	Kawata, Hiromitsu: 3 articles (04/2015 - 12/2010)
3.	Nakagawa, Toshito: 3 articles (04/2015 - 12/2010)
4.	Nakamura, Ryo: 3 articles (04/2015 - 12/2010)
5.	Nishimoto, Ayako: 3 articles (04/2015 - 12/2010)
6.	Sato, Haruhiko: 3 articles (04/2015 - 12/2010)
7.	Shiraishi, Takuya: 3 articles (04/2015 - 12/2010)
8.	Tachibana, Kazutaka: 3 articles (04/2015 - 12/2010)
9.	Yoshino, Hitoshi: 3 articles (04/2015 - 12/2010)
10.	Emura, Takashi: 2 articles (04/2015 - 12/2010)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 04/01/2015 - "In cynomolgus monkeys, the serum concentration of CH5137291 increased dose-dependently and PSA level decreased 80% at 100 mg/kg. CH5137291 is expected to offer a novel therapeutic approach against major types of castration-resistant prostate cancers." 12/01/2010 - "Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model." 04/01/2015 - "CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells." 09/01/2011 - "Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291." 12/01/2010 - "Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer."
2.	Neoplasms (Cancer) 04/01/2015 - "CH5137291 inhibited the growth of LNCaP tumors that had become resistant to bicalutamide treatment. " 04/01/2015 - "In xenograft models, CH5137291 strongly inhibited the tumor growth of LNCaP, LNCaP-BC2, and LNCaP-CS10, whereas bicalutamide showed a weaker effect in LNCaP and almost no effect in LNCaP-BC2 and LNCaP-CS10 xenografts. " 12/01/2010 - "Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model."

Related Drugs and Biologics

1.	Androgen Receptors (Androgen Receptor)
2.	bicalutamide (Casodex)

Related Therapies and Procedures

1.	Castration